---
url: https://www.servicesaustralia.gov.au/cardiomyopathy
title: Cardiomyopathy - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:40:10.526Z
source: servicesaustralia.gov.au
---
# Cardiomyopathy

The PBS subsidises mavacamten for patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), and tafamidis for patients with transthyretin amyloid cardiomyopathy.

## on this page

-   [Patient eligibility](#a1)
-   [Treatment specifics](#a2)
-   [Authority applications](#a3)
-   [More information](#a4)

## Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with mavacamten under the _National Health Act 1953_, section 85 for adult patients with symptomatic obstructive HCM.

The PBS subsidises treatment with tafamidis under the _National Health Act 1953_, section 85 for patients with transthyretin amyloid cardiomyopathy.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home) on the PBS website outlines the restrictions for prescribing mavacamten and tafamidis.

## Treatment specifics

To be eligible for PBS-subsidised treatment with mavacamten, patients must be treated by either a:

-   cardiologist
-   consultant physician with experience in the management of HCM.

To be eligible for PBS-subsidised treatment with tafamidis, patients must be treated by and the authority application completed by, either a:

-   cardiologist
-   consultant physician with experience in the management of amyloid disorders.

## Authority applications

### Mavacamten

#### Applying for initial treatment

Please note: You don’t need to complete this application in writing when you request [PBS authority online](/apply-for-pbs-authority?context=20).

Applications for initial authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:

-   using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20#accordion1)
-   in writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   in writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [symptomatic obstructive hypertrophic cardiomyopathy - mavacamten - initial authority application form](/pb360?context=20)
-   relevant attachments.

#### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised mavacamten to treat symptomatic obstructive HCM can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drug Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

### Tafamidis

Please note: You’ll get an immediate assessment when you request [PBS authorities online](/apply-for-pbs-authority?context=20#accordion1).

#### Applying for initial treatment

AApplications for initial authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form](/pb358?context=20)
-   relevant attachments.

#### Applying for initial grandfather treatment

Applications for initial grandfather authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either in:

-   real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   writing and use [HPOS Form upload](/upload-forms-hpos?context=20)
-   writing and mail to [PBS Complex Drugs Programs](/health-professionals-contact-information?context=20#complexdrugs).

All written applications must include:

-   details of the proposed prescription or prescriptions
-   the completed [transthyretin amyloid cardiomyopathy - tafamidis - initial authority application form](/pb358?context=20)
-   relevant attachments.

#### Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised tafamidis to treat transthyretin amyloid cardiomyopathy can be made either:

-   in real time using the [Online PBS Authorities system](/apply-for-pbs-authority?context=20)
-   by calling the [PBS Complex Drug Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs).

## More information

Call the [PBS Complex Drugs Programs enquiry line](/health-professionals-contact-information?context=20#complexdrugs) for more information.
